TG Therapeutics Inc. (NASDAQ: TGTX) announced four data presentations for its multiple sclerosis treatment BRIUMVI at the 2026 Consortium of Multiple Sclerosis Centers annual meeting in Charlotte, North Carolina.

The presentations will occur on May 28, 2026, featuring results from the company's ongoing ENABLE Phase 4 study and real-world data analyses. One oral presentation will focus on patient-reported outcomes from the ENABLE study, while three poster presentations will cover real-world transition data, infusion tolerability, and breast milk concentration findings.

According to the company's announcement, the ENABLE study data shows patients transitioning from prior anti-CD20 therapies to BRIUMVI maintained a 99.4% relapse-free rate with an annualized relapse rate of 0.011. The study also reported improvements in treatment satisfaction and physical and psychological impact measures beginning at Day 15 and continuing through Week 48.

BRIUMVI is approved by the U.S. Food and Drug Administration for treating adults with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. The drug is a monoclonal antibody that targets CD20-expressing B-cells.

The presentations will include data from the ULTIMATE Phase 3 clinical program, which enrolled 1,094 patients across 10 countries. Additional studies being presented include infusion tolerability analysis and an interim report on BRIUMVI presence in breast milk from the PROVIDE study.

TG Therapeutics is a commercial-stage biotechnology company focused on B-cell disease treatments. The company has received regulatory approval for BRIUMVI in the United States and several countries outside the U.S. for treating relapsing multiple sclerosis.